Cellular processing of platinum anticancer drugs

@article{Wang2005CellularPO,
  title={Cellular processing of platinum anticancer drugs},
  author={D. Wang and S. Lippard},
  journal={Nature Reviews Drug Discovery},
  year={2005},
  volume={4},
  pages={307-320}
}
  • D. Wang, S. Lippard
  • Published 2005
  • Biology, Medicine
  • Nature Reviews Drug Discovery
  • Cisplatin, carboplatin and oxaliplatin are platinum-based drugs that are widely used in cancer chemotherapy. Platinum–DNA adducts, which are formed following uptake of the drug into the nucleus of cells, activate several cellular processes that mediate the cytotoxicity of these platinum drugs. This review focuses on recently discovered cellular pathways that are activated in response to cisplatin, including those involved in regulating drug uptake, the signalling of DNA damage, cell-cycle… CONTINUE READING
    2,642 Citations

    Figures, Tables, and Topics from this paper

    Inhibition of transcription by platinum antitumor compounds.
    • 393
    • PDF
    Understanding and improving platinum anticancer drugs--phenanthriplatin.
    • 191
    Cellular Responses to Cisplatin-Induced DNA Damage
    • 302
    • PDF
    The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy.
    • 377
    Action of the anticancer drug cisplatin investigated by molecular simulation
    • Highly Influenced
    • PDF
    Understanding and Improving Platinum Anticancer Drugs
    • 1

    References

    SHOWING 1-10 OF 234 REFERENCES
    Recognition of cisplatin adducts by cellular proteins.
    • 308
    Cellular and molecular pharmacology of oxaliplatin.
    • 443
    Current status of the development of trans-platinum antitumor drugs.
    • 102
    Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes.
    • A. Eastman
    • Chemistry, Medicine
    • Chemico-biological interactions
    • 1987
    • 139
    Protein interactions with platinum-DNA adducts: from structure to function.
    • 87
    Decreased cisplatin uptake by resistant L1210 leukemia cells.
    • 67